Amgen Inc.
AMGN
Rank in Stocks
#72
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Share Price
$434.84
Market Cap
$235.09B
Change (1 day)
2.33%
Change (1 year)
43.35%
Country
US
Trade Amgen Inc. (AMGN)
Category
Healthcare
Revenue for Amgen Inc. (AMGN)
Revenue in Jun 2026 TTM: $38.13B
According to Amgen Inc. latest financial reports the company's current revenue (TTM) is $38.13B. In 2024 the company made a revenue of $33.42B an increase over the revenue in the year 2023 that was $28.19B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Amgen Inc. from 2000 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $38.13B | 3.74% |
| 2025 | $36.75B | 9.95% |
| 2024 | $33.42B | 18.57% |
| 2023 | $28.19B | 7.09% |
| 2022 | $26.32B | 1.32% |
| 2021 | $25.98B | 2.18% |
| 2020 | $25.42B | 8.83% |
| 2019 | $23.36B | -1.62% |
| 2018 | $23.75B | 3.93% |
| 2017 | $22.85B | -0.62% |
| 2016 | $22.99B | 6.14% |
| 2015 | $21.66B | 7.97% |
| 2014 | $20.06B | 7.43% |
| 2013 | $18.68B | 8.17% |
| 2012 | $17.27B | 10.80% |
| 2011 | $15.58B | 3.51% |
| 2010 | $15.05B | 2.81% |
| 2009 | $14.64B | -2.41% |
| 2008 | $15.00B | 1.57% |
| 2007 | $14.77B | 3.53% |
| 2006 | $14.27B | 14.79% |
| 2005 | $12.43B | 17.82% |
| 2004 | $10.55B | 26.26% |
| 2003 | $8.36B | 51.29% |
| 2002 | $5.52B | 37.54% |
| 2001 | $4.02B | 16.45% |
| 2000 | $3.45B | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $79.67B | 108.96% |
US
|
|
| $99.34B | 160.55% |
US
|
|
| $64.39B | 68.88% |
US
|
|
| $66.40B | 74.16% |
US
|
|
| $77.52B | 103.33% |
CH
|
